{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T06:58:39Z","timestamp":1790665119549,"version":"4.1.0"},"reference-count":19,"publisher":"Wiley","license":[{"start":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T00:00:00Z","timestamp":1790553600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T00:00:00Z","timestamp":1790553600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["shmpublications.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Journal of Hospital Medicine"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>An 81\u2010year\u2010old man with a history of high\u2010grade urothelial carcinoma of the bladder and ureter on treatment with atezolizumab and tiragolumab presented to the emergency department with 5 months of malaise, generalized weakness, and fatigue and 2 weeks of subjective fevers. One month prior to presentation, he received an empiric 9\u2010day course of levofloxacin for possible epididymitis based on\u00a0scrotal pain and an ultrasound showing mild bilateral epididymal prominence. Blood and urine cultures were negative. His constitutional symptoms persisted, and he developed a subjective fever 2 weeks prior to presentation. He was admitted for further evaluation.<\/jats:p>","DOI":"10.1002\/jhm.70442","type":"journal-article","created":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T06:10:47Z","timestamp":1790662247000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Old disease, new twist"],"prefix":"10.1002","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-7333-950X","authenticated-orcid":false,"given":"Hadi","family":"Roudsari","sequence":"first","affiliation":[{"name":"Department of Medicine University of California, San Francisco San Francisco California USA"},{"name":"Division of Hospital Medicine University of California, San Francisco San Francisco California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6134-5913","authenticated-orcid":false,"given":"Gurpreet","family":"Dhaliwal","sequence":"additional","affiliation":[{"name":"Department of Medicine University of California, San Francisco San Francisco California USA"},{"name":"San Francisco Veterans Affairs Medical Center San Francisco California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anand D.","family":"Jagannath","sequence":"additional","affiliation":[{"name":"Division of Hospital Medicine Oregon Health and Science University Portland Oregon USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8840-8825","authenticated-orcid":false,"given":"Alan H.","family":"Baik","sequence":"additional","affiliation":[{"name":"Department of Medicine University of California, San Francisco San Francisco California USA"},{"name":"Division of Cardiology University of California, San Francisco San Francisco California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7656-7490","authenticated-orcid":false,"given":"Sam","family":"Brondfield","sequence":"additional","affiliation":[{"name":"Department of Medicine University of California, San Francisco San Francisco California USA"},{"name":"Division of Hematology\/Oncology University of California, San Francisco San Francisco California USA"},{"name":"UCSF Helen Diller Family Comprehensive Cancer Center San Francisco California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,9,28]]},"reference":[{"issue":"26","key":"e_1_2_7_2_1","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1056\/NEJMoa1200694","article-title":"Safety and activity of anti\u2010PD\u2010L1 antibody in patients with advanced cancer","volume":"366","author":"Brahmer JR","year":"2012","journal-title":"N Engl J Med"},{"issue":"5","key":"e_1_2_7_3_1","doi-asserted-by":"crossref","first-page":"3044","DOI":"10.3390\/curroncol29050247","article-title":"Immune checkpoint inhibitors in cancer therapy","volume":"29","author":"Shiravand Y","year":"2022","journal-title":"Curr Oncol"},{"issue":"1","key":"e_1_2_7_4_1","doi-asserted-by":"crossref","first-page":"3801","DOI":"10.1038\/s41467-020-17670-y","article-title":"A decade of immune\u2010checkpoint inhibitors in cancer therapy","volume":"11","author":"Robert C","year":"2020","journal-title":"Nat Commun"},{"issue":"1","key":"e_1_2_7_5_1","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1038\/s41467-022-27960-2","article-title":"Immune\u2010related adverse events and the balancing act of immunotherapy","volume":"13","author":"Conroy M","year":"2022","journal-title":"Nat Commun"},{"issue":"2","key":"e_1_2_7_6_1","doi-asserted-by":"crossref","first-page":"339","DOI":"10.4143\/crt.2020.790","article-title":"The pattern of time to onset and resolution of immune\u2010related adverse events caused by immune checkpoint inhibitors in cancer: a pooled analysis of 23 clinical trials and 8,436 patients","volume":"53","author":"Tang SQ","year":"2021","journal-title":"Cancer Res Treat"},{"issue":"2","key":"e_1_2_7_7_1","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.alit.2022.01.001","article-title":"Immune\u2010related adverse events in various organs caused by immune checkpoint inhibitors","volume":"71","author":"Okiyama N","year":"2022","journal-title":"Allergol Int"},{"issue":"11","key":"e_1_2_7_8_1","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1161\/CIRCRESAHA.120.315894","article-title":"Mechanisms of cardiovascular toxicities associated with immunotherapies","volume":"128","author":"Baik AH","year":"2021","journal-title":"Circ Res"},{"key":"e_1_2_7_9_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2024.102536","article-title":"Clinical spectrum and evolution of immune\u2010checkpoint inhibitors toxicities over a decade\u2014a worldwide perspective","volume":"70","author":"Gougis P","year":"2024","journal-title":"EClinicalMedicine"},{"issue":"6","key":"e_1_2_7_10_1","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002435","article-title":"Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor\u2010related adverse events","volume":"9","author":"Brahmer JR","year":"2021","journal-title":"J Immunother Cancer"},{"issue":"8","key":"e_1_2_7_11_1","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1016\/j.jtho.2018.04.031","article-title":"Sarcoidosis\u2010like reactions induced by checkpoint inhibitors","volume":"13","author":"Gkiozos I","year":"2018","journal-title":"J Thorac Oncol"},{"key":"e_1_2_7_12_1","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.ejca.2021.05.041","article-title":"Immune checkpoint inhibitor\u2013associated sarcoidosis: a usually benign disease that does not require immunotherapy discontinuation","volume":"158","author":"Chanson N","year":"2021","journal-title":"Eur J Cancer"},{"issue":"40","key":"e_1_2_7_13_1","doi-asserted-by":"crossref","first-page":"3952","DOI":"10.1093\/eurheartj\/ehaf192","article-title":"2025 ESC guidelines for the management of myocarditis and pericarditis","volume":"46","author":"Schulz\u2010Menger J","year":"2025","journal-title":"Eur Heart J"},{"issue":"1","key":"e_1_2_7_14_1","first-page":"50","article-title":"Cardiac sarcoidosis\u2010state of the art review","volume":"6","author":"Hulten E","year":"2016","journal-title":"Cardiovasc Diagn Ther"},{"issue":"13","key":"e_1_2_7_15_1","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.3390\/cancers17132063","article-title":"Management of triple M syndrome: a systematic review with narrative synthesis of immune checkpoint inhibitor\u2010induced myasthenia gravis, myositis and myocarditis","volume":"17","author":"Furlepa M","year":"2025","journal-title":"Cancers"},{"issue":"36","key":"e_1_2_7_16_1","doi-asserted-by":"crossref","first-page":"4073","DOI":"10.1200\/JCO.21.01440","article-title":"Management of immune\u2010related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update","volume":"39","author":"Schneider BJ","year":"2021","journal-title":"J Clin Oncol"},{"key":"e_1_2_7_17_1","unstructured":"National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology: management of immunotherapy\u2010related toxicities. National Comprehensive Cancer Network;2024. Accessed October 17 2025.https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/immunotherapy.pdf"},{"issue":"10","key":"e_1_2_7_18_1","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1002\/ejhf.2265","article-title":"Immune checkpoint inhibitor myocarditis: elucidating the spectrum of disease through endomyocardial biopsy","volume":"23","author":"Palaskas NL","year":"2021","journal-title":"Eur J Heart Fail"},{"issue":"1","key":"e_1_2_7_19_1","doi-asserted-by":"crossref","first-page":"251","DOI":"10.3390\/jcm11010251","article-title":"Histology of cardiac sarcoidosis with novel considerations arranged upon a pathologic basis","volume":"11","author":"Kato S","year":"2022","journal-title":"J Clin Med"},{"issue":"21","key":"e_1_2_7_20_1","doi-asserted-by":"crossref","first-page":"e1197","DOI":"10.1161\/CIR.0000000000001240","article-title":"Diagnosis and management of cardiac sarcoidosis: a scientific statement from the American Heart Association","volume":"149","author":"Cheng RK","year":"2024","journal-title":"Circulation"}],"container-title":["Journal of Hospital Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/shmpublications.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jhm.70442","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/shmpublications.onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/jhm.70442","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/shmpublications.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jhm.70442","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T06:10:56Z","timestamp":1790662256000},"score":1,"resource":{"primary":{"URL":"https:\/\/shmpublications.onlinelibrary.wiley.com\/doi\/10.1002\/jhm.70442"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,28]]},"references-count":19,"alternative-id":["10.1002\/jhm.70442"],"URL":"https:\/\/doi.org\/10.1002\/jhm.70442","archive":["Portico"],"relation":{},"ISSN":["1553-5592","1553-5606"],"issn-type":[{"value":"1553-5592","type":"print"},{"value":"1553-5606","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,28]]},"assertion":[{"value":"2026-01-29","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-08-07","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-09-28","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"jhm.70442"}}